Sign In
Buy AKRO
$54.65
+0 (+0%)
At Close: Mar 06, 2026
Why Is Akero Therapeutics (AKRO) Stock Up 120% Today?
10:04am, Tuesday, 13'th Sep 2022
Akero Therapeutics (NASDAQ: AKRO ) stock is soaring 120% and is one of today's top trending tickers on sites like Yahoo Finance. The rally was sparked by the company's release of positive data on its
Akero Therapeutics Wows Investors With Unexpected Win For Hepatitis Treatment
09:28am, Tuesday, 13'th Sep 2022
Akero wowed investors Tuesday with midstage test results for a hepatitis treatment, and the biotech stock skyrocketed by triple digits. The post Akero Therapeutics Wows Investors With Unexpected Win F
Akero Therapeutics to Present Results from Phase 2b HARMONY Trial Investigating Efruxifermin in Patients with Pre-Cirrhotic NASH
04:01pm, Thursday, 08'th Sep 2022
Investor webcast on Tuesday, September 13 at 8:00 a.m. ET to present clinical data Investor webcast on Tuesday, September 13 at 8:00 a.m. ET to present clinical data
Akero Therapeutics (AKRO) Up on Positive NASH Study Data
01:33pm, Thursday, 25'th Aug 2022
Akero Therapeutics (AKRO) announces positive data from third cohort of its mid-stage study evaluating efruxifermin (EFX) in NASH. Stock up.
Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million
11:00am, Thursday, 16'th Jun 2022 GlobeNewswire Inc.
$25 Million Equity Investment by Pfizer at $9.90 Per Share
Akero Therapeutics Shares Surge After Equity Investment From This Famed Large Cap Biopharma
09:24am, Thursday, 16'th Jun 2022
Akero Therapeutics Inc (NASDAQ: AKRO) announced a $25 million equity investment by Pfizer Inc (NYSE: PFE) at $9.90 per share. The company also announced a term loan facility providing Akero wit
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
08:05pm, Wednesday, 01'st Jun 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious me
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
04:05pm, Wednesday, 01'st Jun 2022
SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious meta
Akero Therapeutics Reports First Quarter 2022 Financial Results
11:00am, Friday, 06'th May 2022 GlobeNewswire Inc.
Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year
Akero Therapeutics to Present at Upcoming Healthcare Conferences in May
11:30am, Monday, 02'nd May 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, May 02, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic d
Zacks Investment Research Downgrades Akero Therapeutics to Sell
07:43am, Thursday, 03'rd Mar 2022 Business Mag
Akero Therapeutics was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday, Zacks.com reports. According to Zacks…
Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
12:00pm, Friday, 25'th Feb 2022 GlobeNewswire Inc.
Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year
Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
12:00pm, Friday, 25'th Feb 2022 GlobeNewswire
Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year
Akero finishes enrollment in phase 2b trial of efruxifermin in liver disease
06:46pm, Tuesday, 08'th Feb 2022 Seeking Alpha
Akero Therapeutics (AKRO) completed enrollment in a phase 2b study, dubbed HARMONY, evaluating efruxifermin ((EFX)) to treat non-alcoholic steatohepatitis ((NASH))
Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients
01:00pm, Tuesday, 08'th Feb 2022 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that it has completed enrollment of the Phase 2b HARMONY study of efruxifermin (EFX), a novel FGF21 analog, for the treatment of non-alcoholic steatohepatitis (NASH).
